The recurrence of breast cancer in patients is a persistent challenge to the medical fraternity. Breast tumor contains a small population of cells with high tumor initiating and metastatic potential, known as cancer stem cells (CSCs), which are resistant to existing chemotherapeutics. CSCs contribute to the aggressiveness of triple negative breast cancers (TNBCs), thereby necessitating the identification of molecular targets on breast CSCs. TNBC cell line MDA-MB-231, in comparison with MCF-7, demonstrated a higher expression of epidermal growth factor receptor (EGFR). Thus, the naturally occurring flavanone, chrysin, with limited potential as a chemotherapeutic agent, was structurally modified by designing an analog with EGFR binding affinity using a molecular docking approach and subsequently synthesised. Chrysin analog CHM-09 and known EGFR inhibitors demonstrated a comparable anti-proliferative, anti-migratory activity along with the induction of apoptosis and cell cycle arrest in MDA-MB-231. Furthermore, sorted CD24 À / CD44 + -breast CSCs and CD24 + -breast cancer cells from MDA-MB-231 demonstrated a markedly high expression of EGFR in the former than in the latter. CHM-09 and EGFR inhibitors could perturb EGF-induced EGFR signalling of breast CSC proliferation, migration, mammosphere formation and mesenchymal tri-lineage differentiation. CHM-09 or EGFR inhibitors not only led to inactivation of EGFR downstream signalling pathways such as Akt, extracellular signal regulated kinase and signal transducer and activator of transcription 3, but also induction of mesenchymal-epithelial transition as confirmed by decreased N-cadherin and increased E-cadherin expression. Finally, combinatorial treatment of EGFR inhibitors and doxorubicin led to significant increase in breast CSCs responsiveness to a chemotherapeutic drug. The results of the present study suggest that EGFR is a therapeutic target in breast CSCs and that abrogation of EGFR signalling along with chemotherapeutic drugs is an effective approach against breast cancer.
Introduction
Cancer is an imbalance between cell division and death that favours the unlimited growth of a tumor. Various tissue-specific cancers such as breast, lung and liver, occur as a result of DNA mutations caused by physical or chemical mutagens. Among these, breast cancer is the second most common cause of morbidity and mortality in women [1] . To date, several anticancer therapeutics have been targeted against a number of receptor tyrosine kinases (RTK) known to play major role in tumorigenesis by activating downstream signalling [2] . Among the RTKs, transforming growth factor receptor-b has been reported to promote breast cancer metastasis through induction of epithelial to mesenchymal transition (EMT) [3] , vascular endothelial growth factor receptor as a mediator of breast tumor angiogenesis [4] and platelet-derived growth factor receptor as a predominant signalling pathway in the maintenance of mesenchymal phenotype of breast cancer [5] . The literature suggests a crucial role of epidermal growth factor receptor (EGFR) in breast cancer cell proliferation and migration [6] . EGFR belongs to the ErbB tyrosine kinase family that comprises of four receptors: EGFR/ErbB1, HER2/ErbB2, HER3/ ErbB3 and HER4/ErbB4 [7] . Among these, EGFRs are highly expressed in human malignant tumors [8] , although they are poor prognostic factors in breast cancer [9] . The activation of EGFR phosphorylates its downstream signalling molecules, Akt and signal transducer and activator of transcription (STAT)3, which are involved in cellular migration and mitogen-activated protein kinase signalling, as implicated in cell proliferation [10] . Breast cancer patients treated with EGFR inhibitors such as erlotinib and gefitinib have shown minimum clinical activity [11] but reduced sideeffects compared to conventional chemotherapeutic drugs [12] . Therefore, it is pertinent to target EGFR signalling with more potent inhibitors that are naturally derived chemicals as cancer therapeutics.
Chrysin, a flavonoid, is a natural phytochemicalabundantly found in many plant extracts. It demonstrates cytotoxicity against colon, lung, cervical, liver, prostate and pancreatic cancer [13] . The use of chrysin as a chemotherapeutic agent has limitations such as poor therapeutic potential and poor absorption, rapid metabolism and fast systemic elimination [14] . Although liposomal nanoparticles conjugated with chrysin have been used for efficient anticancer drug delivery [15] , we hypothesize that the design of synthetic analogs of chrysin against a specific molecular target may improve its efficacy as a chemotherapeutic agent.
Despite the available chemotherapeutic agents against breast cancer, the reoccurrence of cancer often arises as a result of the presence of a small sub-population of cancer cells known as cancer stem cells (CSCs). CSCs are tumor-initiating cells with selfrenewal ability and high metastatic potential [16] . CSCs are resistant to existing chemotherapy and radiotherapy because of the higher expression of efflux transporters, an enhanced DNA repair mechanism and resistance to apoptosis [17] .
In the present study, a higher expression of EGFR was observed in aggressive triple negative breast cancer (TNBC) cell line, MDA-MB-231, compared to a luminal breast cancer cell line, MCF-7. This led us to design and synthesize a chrysin analog, CHM-09, that binds to EGFR, as confirmed by molecular docking studies and cellular thermal shift assays (CETSA 1A) and immunoblotting (Fig. 1B) demonstrated a relatively high level in MDA-MB-231 compared to MCF-7. This observation suggests a crucial role of EGFR in the aggressive TNBC types, which is associated with a poor prognosis and reduced survival in patients [18] .
Molecular docking of chrysin analogs on EGFR
Chrysin (Fig. 1C) , a naturally occurring flavanone with limited clinical potential as an anticancer agent, led us to design using chemical docking approach and synthesize its analog, CHM-09 ( Fig. 1D ) with an improved binding affinity to EGFR (Fig. 1E) . The low resolution X-ray crystal structures of different EGFR [Protein Data Bank (PDB) code: 3W32, 3W33, 3POZ and 3W2R] complexed with co-ligands have been retrieved from RCSB protein data bank (www.rcsb.org). The final selection of EGFR was performed on the basis of the docking accuracy by calculating the rmsd. The rmsd values were calculated by superimposing best docked poses of co-ligands on its native co-ligand. The rmsd value has been observed to be the lowest for 3W32 (0.8254) ( Table 1 ). The XP glide scores of co-ligands with receptors 3W32 and 3W33 were À14.297 and À12.624, respectively, and the important interacting amino acid residues were observed to be Met793, Phe856, Leu718 (Fig. 1F) . The interacting amino acid residues for CHM-09 were observed to be Met793, Asp855 (2) À12.187 (Fig. 1E,F) . Similarly, molecular docking of commercially available EGFR inhibitors AG-1478 and PD-153035 demonstrated that Asp855 is the crucial amino acid residue for inhibition, which is also present in case of CHM-09 (data not shown). Other than the common interactions with EGFR inhibitors, CHM-09 also showed interactions with Met793 and Lys745. Based on the active site amino acid residues and the XP glide score of both CHM-09 and coligands (Fig. 1G,H) , chrysin was isolated from the bark of Oroxylum indicum ( Fig. 2A) , and chrysin analog, CHM-09, was synthesized as described in the scheme (Fig. 2B ) and characterized using spectral analysis (Fig. 2C,D (Fig. 3A) . The significant shift in melting temperatures of EGFR and its stabilization upon addition of the CHM-09 indicated that both the compounds bind to this protein.
Proliferation of breast cancer cells by EGFR inhibitors
Next, we evaluated the anti-proliferative potential of our synthesized chrysin analog, CHM-09 and compared it with its parent molecule, chrysin, and EGFR inhibitors, AG1478 and PD153035, using cell viability assays. The compound CHM-09 demonstrated a higher efficacy against a panel of TNBC cell lines, MDA-MB-231 (Fig. 3B) , MDA-MB-453 (Fig. 3C) , MDA-MB-468 ( Fig. 3D ) and BT-549 ( Fig. 3E) (Fig. 3G) . These results correlated well with EGFR expression levels in these breast cancer cell lines, indicating that chrysin analog, CHM-09, with an improved EGFR binding ability, effectively decreases the cell viability in TNBC cell lines that express relatively high EGFR.
Modulation of aggressive TNBC cell cycle and apoptosis by EGFR inhibitors
To further substantiate the in vitro anti-proliferative effect of EGFR inhibitors and/or chrysin analog, CHM-09, at a low micromolar range on MDA-MB-231 cells, we evaluated bromodeoxyuridine (BrdU) incorporation using cell cycle analysis. CHM-09-treated cells demonstrated 62.3% of cells in the G 0 /G 1 phase of the cell cycle compared to 53.3% in the vehicle control group (Fig. 4A) indicating G 0 /G 1 cell cycle arrest. Treatment with EGFR inhibitors, AG1478 and PD153035, also resulted in G 0 /G 1 cell cycle arrest (62.4% and 64.5%, respectively). The expression of unique cyclins and cyclin-dependent kinases (CDKs) along with CDK inhibitors (CKIs) occurs during the cell cycle progression. The gene expression levels of cyclin D, cyclin E and their CDK partner, CDK2, which regulates the G 0 /G 1 phase, were markedly decreased in cells treated with inhibitors, as well as CHM-09, compared to vehicle control (Fig. 4B) .
To further corroborate the cell cycle gene expression of EGFR inhibitors and/or chrysin analog, CHM-09, on MDA-MB-231 cells, we also evaluated the protein expression levels. Expression of CDK4 and CDK2 and their partners cyclin D and cyclin E regulates the G 1 phase of the cell cycle and was markedly decreased in cells treated with inhibitors, indicating the accumulation of cells at the G 0 /G 1 phase (Fig. 4C) . These results correlated well with the BrdU cell cycle analysis data. By contrast, cyclin B regulates the G 2 /M phase of cell cycle, which was increased, whereas, with CDK1, no obvious changes were observed in the presence of inhibitors compared to vehicle control, indicating M phase progression. This observation was further substantiated by concomitant increased expression of CKI, p21 and decreased expression of p27 in the presence of inhibitors (Fig. 4C) , suggesting a major role of p21 in preventing the CDK4 and CDK2 complexes and their interacting partners, thereby arresting cells at the G 0 /G 1 phase of cell cycle. These results collectively suggest apoptotic cell death as a result of these treatments, leading us to evaluate apoptotic populations using flow cytometric analysis. A significantly high percentage (approximately 98.4%) of cells was observed to undergo apoptosis in CHM-09-treated cells compared to vehicle control (Fig. 5A) . Similarly, the EGFR inhibitors AG1478 and PD153035 induced apoptosis by 84.4% and 94.5%, respectively (Fig. 5A ). Further substantiating this observation, expression levels of pro-apoptotic genes, Bax and Bid (Fig. 5B) , as well as proteins, BAX, caspase3 and annexin V ( EGFR activation has been associated with multiple biological processes in cancer progression, such as cell proliferation, migration and metastasis through different signalling pathways [20] . To evaluate the effect of CHM-09 on signal transduction mechanism, we performed immunoblot analysis of EGFR downstream signalling pathways: Akt, extracellular signal regulated kinase (ERK) and STAT3. Aggressive TNBC MDA-MB-231 cells that express high EGFR were treated with increasing concentrations of CHM-09 and demonstrated a dose-dependent decrease in phosphorylation of EGFR, Akt, ERK and STAT3 (Fig. 6A) . A similar CHM-09-mediated dose-dependent decrease in the phosphorylation of these signalling mediators was also observed in BT-549 (Fig. 6B ), MDA-MB-453 ( Fig. 6C ) and MDA-MB-468 (Fig. 6D) . b-catenin, a downstream target of Akt signalling pathway [21] , was also down-regulated in CHM-09-treated cells, indicating that Akt attenuation leads to down-regulation (decrease in phosphorylation) of b-catenin. Inhibition of EGFR by PD153035 also abolished activation of the Akt, STAT3 and ERK signalling pathways responsible for cell migration and proliferation, respectively (Fig. 7A ). To confirm whether this observation holds true, we performed a proliferation assay in MDA-MB-231 cells treated with EGF in the presence/absence of EGFR, ERK, Akt and STAT3 signalling blockers at the indicated doses. The EGFinduced proliferation was significantly decreased by CHM-09 similar to EGFR inhibitors, AG1478 and PD153035 (Fig. 7B) . Also wortmannin, PD98059 and static inhibitors of Akt, ERK and STAT3, respectively, could significantly decrease EGF-induced proliferation (Fig. 7B) . Furthermore, the addition of CHM-09 along with EGFR inhibitors or Akt and ERK inhibitors did not alter the cellular proliferation compared to when they were added separately (Fig. 7B ). However, a combination of CHM-09 and static significantly reduced proliferation compared to static alone ( migration was evaluated temporally at the 6-, 12-and 24-h time points. EGF-induced migration was significantly attenuated by these inhibitors at the treated concentrations (Fig. 7C) . Combinations of CHM-09 with these pathway inhibitors demonstrated a further significant decrease in cell migration by wortmannin and static (Fig. 7C) , suggesting a role of EGFR-AKT and EGFR-STAT3 signalling-mediated regulation of cell migration in aggressive TNBCs (Fig. 7C) . Aggressive properties of TNBCs are the result of a small highly migratory population known as the breast CSCs, which differentially express a specific cluster of differentiation (CD) markers on their cell surface [22, 23] . cell proliferation (n = 6) and (C) cell migration (n = 4). Data are the mean AE SEM of three independent experiments. P < 0.05 (t-test) compared to control (*), EGF-treated (#) and EGF-treated + respective signaling inhibitor ($) groups. P < 0.01 (t-test) compared to control (**) and EGF-treated (##) groups. (Fig. 8A) . Subsequently CD24 À cell populations were further subjected to CD44 selection (Fig. 8A) . The sorted CD24 À /CD44 + (breast CSCs; percentage yield of total: 9.3 AE 1.6) cells expressed CD44 and were negative for CD24, whereas CD24 + (breast cancer cells; percentage yield of total: 42.9 AE 6.1) were positive for CD24 cell surface markers as analyzed using confocal imaging (Fig. 8B) . Additionally, flow cytometry analysis revealed that 77.5% of CD44 expressing cells were negative for CD24 surface marker expression, thereby confirming the purity of these CD24
High EGFR expression in breast CSCs
À /CD44 + sorted fractions (Fig. 8C) . Upon characterization, CD24 À /CD44 + demonstrated a marked increase in CSC-specific gene expression, ALDH1, MUC1, ABCG2 and CD133 (Fig. 8D) , compared to CD24 + sorted populations. CD24 gene expression was lacking in the CD24 À /CD44
+ population (Fig. 8D) . ALDH1, an enzyme that is expressed at high levels in CSCs, is known to be major characteristic feature of breast CSCs. Our sorted populations, CD24
+ exhibited a 100% aldefluor fluoroscence compared to control (diethyl amino benzaldehyde) indicating an ALDH + population (Fig. 8E) . Encouragingly, a markedly high level of EGFR expression was observed in CD24 À /CD44 + compared to CD24 + sorted cell populations (Fig. S1) (Fig. 9B) . The effect of CHM-09 on breast CSCs was 1.7-to 4.0-fold higher than EGFR inhibitor, PD153035 (Fig. 9A) . This observation suggests that a higher expression of EGFR in breast CSCs compared to breast cancer cells leads to a better inhibition of EGFR by these inhibitors, thereby modulating further downstream signalling-mediated cell viability.
Attenuation of EGFR downstream signalling in breast CSCs
To further support the observation of EGFR inhibition leading to a decrease in the physiological phenotype of breast CSCs, we explored the downstream signalling of EGFR in the presence of CHM-09, as well as various receptor blockers, using immunoblotting techniques. An EGF-induced increased phosphorylation of EGFR, as well as its downstream kinases, ERK, Akt and STAT3 (transcription factor), was observed (Fig. 9C) . Inhibition of EGFR by PD153035 or CHM-09 decreased the phosphorylation of Akt, ERK and STAT3 in the presence of EGF, indicating that EGFR blocking leads to abrogation of downstream signalling pathways (Fig. 9C) . The use of specific pathway blockers decreased the activation of these signalling mediators. Next, to confirm whether the downstream signalling pathway of EGFR holds true in CD24 À /CD44 + -breast CSCs, we evaluated the EGF-induced proliferation in combination of EGFR inhibitor and other pathway blockers. Indeed, EGFinduced increased proliferation of breast CSCs was significantly inhibited by these pathway blockers individually (Fig. 9D) . However, no further decrease in proliferation was observed when treated along with CHM-09 (Fig. 9D) . This observation suggests the role of EGFR signalling in the maintenance of stemness (mammospheres, etc.) in breast CSCs.
EGFR inhibition suppresses EGF-induced breast CSC properties: mammosphere formation and migration
The stemness properties of breast CSCs are often evaluated using an in vitro assay system, where these breast CSCs are enriched in suspension cultures as 'mammospheres' that imitate in vivo tumors [24] . The breast CSCs sorted from MDA-MB-231 (Fig. 10A-C) , BT-549 (Fig. 10D-F) , MDA-MB-453 and MDA-MB-468 (data not shown), when treated with EGF (10 ngÁmL À1 ), demonstrated significantly larger size mammospheres and higher sphere forming efficiency compared to vehicle control. By contrast, the sphere forming efficiency was significantly decreased by CHM-09 in a dose-dependent manner in the presence or absence of EGF, as well as PD153035, as demonstrated quantitatively (Fig. 10C,  F) . These findings indicate that the EGF-induced in vitro tumor formation ability of breast CSCs was hindered by PD153035 and CHM-09 via an inhibition of EGFR signalling. Metastasis, a crucial phenomenon that occurs as a result of a high migratory potential of breast CSCs, was evaluated further. A significant decrease in EGF-induced migration was observed in the presence of EGFR inhibitor, PD153035 and CHM-09, in a dose-dependent manner (Fig. 11A) . ) and (F) as quantified from representative photomicrographs (n = 4). Scale bar = 50 lm. Data are the mean AE SEM from experiments repeated four times. P < 0.05 (t-test) compared to vehicle control (*) and EGF-treated group (#). cultured in specific differentiation mediums. As described in the Materials and methods, cells grown in chondrocyte differentiation medium stained positively with toluidine blue for the detection of collagen type II. EGF-treated cells demonstrated significantly higher staining by toluidine blue compared to vehicle control (Fig. 11B) , which was inhibited by an increasing dose of CHM-09 (Fig. 11B) or PD153035 (5 lM) (Fig. 11C) , as evaluated quantitatively (Fig. 11D) . Next, for the detection of adipocytes, cells were stained with Oil red O stain, which specifically stains the lipid droplets present in the mature adipocytes. Breast CSCs treated with EGF demonstrated an increased number of lipid droplets compared to vehicle control (Fig. 11E) , which was reduced by an increasing concentration of CHM-09 (Fig. 11E ) or PD153035 at 5 lM (Fig. 11F ) as analyzed quantitatively (Fig. 11G) . Furthermore, for osteoblast differentiation, breast CSCs were cultured in osteoblast differentiation medium and stained with 5% silver nitrate (von Kossa staining) to detect the mineral deposits. EGF-treated cells showed more mineral deposits compared to vehicle control that was attenuated in the presence of CHM-09 in a concentration-dependent manner (Fig. 11H) or PD153035 (5 lM) (Fig. 11I) , as assessed quantitatively (Fig. 11J) . These results demonstrate an induction of EGFR signalling that promotes the mesenchymal phenotype of breast CSCs which was effectively reduced by CHM-09 or PD153035.
EGFR inhibition perturbs the mesenchymal differentiation phenotype of breast CSCs

Inhibition of EGFR signalling induces MET and responsiveness to anticancer drugs in breast CSCs
The epithelial marker, E-cadherin, was down-regulated in EGF treated cells compared to the control (Fig. 12A) . EGFR inhibition in the presence of PD153035 or CHM-09 led to a significant up-regulation of E-cadherin expression, indicating a gain of epithelial phenotype (Fig. 12A) . EGF-induced mesenchymal marker gene expression (e.g. vimentin and fibronectin) was significantly down-regulated in the presence of EGFR inhibition, indicating a loss of mesenchymal phenotype (Fig. 12A) . Interestingly, EMTspecific transcription factors, TWIST1 and ZEB2, along with adhesion molecule, ALCAM, and chemokines, CXCR4 and CXCR6, demonstrated a marked reversal of EGF-induced gene expression in the presence of EGFR inhibition (Fig. 12A) . Similarly, at the protein expression levels, EGFR inhibition also led to marked decrease in vimentin and N-cadherin along with concomitant increase in E-cadherin in breast CSCs sorted from MDA-MB-231 (Fig. 12B, left) and BT-549 (Fig. 12B, right) , as well as MDA-MB-453 (Fig. 12C, left) and MDA-MB-468 (Fig. 12C, right) . These results demonstrate that inhibition of EGFR signalling leads to a reversal of EMT or acquisition of mesenchymal-epithelial transition (MET) by the breast CSCs. Finally, we evaluated the proliferation of our sorted breast CSCs in the presence of doxorubicin, a chemotherapeutic agent. Doxorubicin alone could not inhibit the proliferation of the breast CSCs by more than 33-38%. However, when these breast CSCs isolated from MDA-MB-231 (Fig. 13A) , BT-549 (Fig. 13B) , MDA-MB-453 (Fig. 13C) and MDA-MB-468 (Fig. 13D) were treated with doxorubicin along with EGFR inhibitors, a significantly high percentage of inhibition (approximately 74%) was observed (Fig. 13A) . These results suggest that the inhibition of EGFR signalling leads to an increased responsiveness of breast CSCs to chemotherapeutics.
Discussion
Breast tumor exhibits different sub-types based on its molecular profiling, such as luminal, (type A and type B), HER-2 overexpressing, normal-like and basal-like breast cancer (TNBC) [23] . TNBC is most aggressive form of breast cancer and is associated with increased rate of recurrence and poor patient survival [25] . TNBC cell lines are negative for receptors (estrogen, progesterone and HER-2) and positive for basal markers (cytokeratin5/6 and EGFR) [26] . The results of the present study correlated well with the existing literature indicating that a TNBC cell line, MDA-MB-231 (basal), demonstrated high EGFR expression compared to MCF-7 (luminal). Preclinical breast cancer models and clinical studies suggest that EGFR expression is concomitant with an aggressive phenotype and poor clinical outcome [27] . Furthermore, basal-like tumors do not respond to conventional cancer treatments such as chemotherapy and radiotherapy. The four classes of EGFR inhibitors used for cancer therapy are monoclonal antibodies (cetuximab), antisense oligonucleotides, antibody-based immuno-conjugates and small molecules (RTKs: erlotinib and gefitinib) [26] . These kinase inhibitors prevent auto-phosphorylation of the intracellular tyrosine kinase domain of EGFR [28] . Standard cancer chemotherapy drugs affect the replication of cancer cells, whereas EGFR inhibitors target the crucial pathways of cancer cell growth and survival [29] . As a result of a lack of efficacious small molecule inhibitors against EGFR with lower side-effects, we have synthesized a chrysin analog, CHM-09, with an enhanced binding affinity to the EGFR active site, as confirmed by molecular docking studies and CETSAs. Our observations matched those of previous reports indicating that the cell viability of TNBC cells was significantly reduced in the presence of EGFR blockers [30] . Activation of EGFR signalling in TNBC plays a major role in cancer cell proliferation, migration, EMT and metastasis via activation of downstream signalling cascades [31] . Chrysin analog, CHM-09-treated cells demonstrated a decreased activation of EGFR and its downstream signalling, as reported previously in the literature [7, 8] .
Aggressive TNBC tumors possess a small population of cells with stem cell-like properties of self-renewal and differentiation that are known as breast CSCs [32] . Apart from these, the literature suggests that breast CSCs also show enhanced migration and invasion properties aiding metastasis [33] . Metastatic human breast CSCs form mammospheres as a result of stem cell properties [24] . Observations depicting the large mammosphere forming efficiency of our sorted breast CSCs support this important characteristic feature of self-renewal capacity [34] . The breast CSCs bearing a mesenchymal phenotype exhibit a tri-lineage ability to differentiate into adipocytes, chondrocytes and osteoblasts similar to mesenchymal stem cells [35] . Cancer cells that are epithelial in nature are sensitive to chemotherapies [36] . The loss of epithelial phenotype (E-cadherin) and gain of mesenchymal phenotype (vimentin, N-cadherin and fibronectin) leads to chemoresistance in breast CSCs as a result of the perturbation of important signal transduction pathways [37] . Thus, molecular targeted therapies against a specific signalling mediator provide encouragement with respect to the survival of breast cancer patients against a metastatic relapse of disease [38] . The recent literature has suggested that chemotherapeutic drugs such as paclitaxel, salinomycin, doxorubicin and etoposide inhibit tumor growth and the metastasis of CSCs with limited efficiency [17] , which is similar to our observation regarding the very low inhibition of proliferation in our sorted breast CSCs by doxorubicin. EGFR is an important therapeutic target and its high expression in breast CSCs compared to cancer cells makes it a preferred molecular target for inhibiting CSC metastasis and the recurrence of cancer. Our data demonstrating that the attenuation of EGFR signalling led a to reversal of EMT or the induction of MET in breast CSCs, along with an increased responsiveness to chemotherapeutics when simultaneously treated with doxorubicin and EGFR inhibitors, suggest that this is an effective therapeutic approach for suppressing tumorigenicity and preventing metastasis in EGFR expressing breast CSCs.
Materials and methods
Isolation of chrysin
The air-dried stem bark of O. indicum (a voucher specimen #BD-02/07 has been deposited in the National Herbarium, Government of India, Shibpur, Howrah) was crushed into powder and extracted with cold methanol [39] . The dried methanol extract was dissolved in 150 mL of water and fractionated by solvent extraction using petroleum ether, chloroform and n-butanol, successively (20 9 3 mL each). Both chloroform and the n-butanol fraction on column chromatography with silica gel (60-120 mesh; Merck, Darmstadt, Germany) eluting with PE-EtOH (7 : 3) gave light yellow crystals of chrysin (1.3 g).
Chemical characterization of isolated chrysin
The melting point of the compound was 270°C. It was then characterised by 1 H, 13 C NMR spectral analysis and compared with the spectral data of an authentic sample. 
Spectral data of chrysin
Protein preparation and grid generation
The X-ray crystal structures of EGFR with low resolution have been retrieved from the RCSB protein data bank Fig. 11 . EGFR inhibition perturbs the migratory potential as well as a tri-lineage differentiation ability in breast CSCs. (A) A time-and dosedependent increase in EGF-induced migration of breast CSCs was significantly inhibited by EGFR blockers, CHM-09 and PD153035 (n = 4). EGF-induced collagen deposition was significantly reduced in the presence of (B) CHM-09 and (C) EGFR inhibitor, PD153035, and (D) quantification of representative photomicrographs as demonstrated in a chondrocyte differentiation assay (n = 6). EGF treatment leads to an accumulation of oil O droplets that were decreased in the presence of (E) CHM-09 and (F) PD153035. (G) A representative image for quantification as observed in a adipocyte differentiation assay (n = 6). In addition, EGF-induced mineral deposits were significantly blocked by EGFR inhibition using (H) CHM-09 and (I) PD-153035. (J) Photomicrograph quantification as revealed in an osteoblast differentiation assay (n = 6). Quantification of photomicrographs was performed using NIH IMAGEJ software. Data are representative of more than three independent experiments. P < 0.05 compared to vehicle control (*) and EGF-treated group (#). (www.rcsb.org). EGF receptors (PDB codes: 3W32, 3W33, 3POZ and 3W2R) [40, 41] complexed with co-ligands were prepared using the 'Protein Preparation Wizard' [42] . Protein was pre-processed, optimized and minimized with the force field of OPLS_2005. The prepared protein was used for grid generation using the 'Receptor Grid Generation' panel. The grid box has been defined with a size of 15 A from the centre of selected co-crystallized ligand.
Docking validation
The docking accuracy has been evaluated by calculating the rmsd. The lower the rmsd value, the higher the docking accuracy and, for precise glide docking, the value should be < 1.0 [43] . The rmsd values were calculated by superimposing the best docked poses of co-ligands on the native coligand and are summarized in Table S1 . The rmsd value of 3W32 was 0.8254, which was found to be the lowest and was chosen for the docking study. All the of computational work were carried out using am HP Z820 Workstation (Hewlett-Packard, Palo Alto, CA, USA) running CentOS 6.3 (https://www.centos.org).
Chemical synthesis of chrysin analog (CHM-09)
For transformation of compound 1 to compound 3, a mixture of 1 (0.100 g, 0.393 mmol), t-butylbromoacetate (0.1228 g,0.393 mmol), K 2 CO 3 (0.110 g, 0.795 mmol) and 20 mL of dried acetone was stirred at room temperature for 3 h and starting material 1 disappeared [44] . The reaction mixture was dried in rotary evaporator at 40°C followed by extraction with ether and the residue was subjected to column chromatography over silica gel eluate PE-EtOH (9 : 1) to give compound 2 (0.1250 g, yield: 86%) [45] . The compound was kept in vacuum desiccator overnight. Trifluro acetic acid was added drop by drop to compound 2 and dried in rotary evaporator and the resulting compound 3 was obtained (0.0946 g, yield: 88.7%). To a solution of compound 3 (0.090 g, 0.288 mmol) in 15 mL of dried DMF, DCC (0.090 g, 1.5 eq) was added and the solution was heated at 90-95°C. After 5 min, dopamine (0.045 g, 1 eq), triethyl amine (0.045 g, 1.5 eq) and DMAP (1 mg) were added to the solution with continued heating at 90-100°C. After 24 h, compound 3 disappeared on TLC from the reaction mixture and the mixture was dried under a reduced pressure to a semi-solid mass. This was then suspended in minimum volume (10 mL) of distilled water and extracted with ethyl acetate (3 9 10 mL). The ethyl acetate extracts were mixed together, washed with brine and dried under a reduced pressure. The residue was purified using silica gel column chromatography and eluent petroleum etherethylacetate (8 : 2 ratio) gave CHM-09(U) (0.065 g yield: 43.51%), whereas eluent petroleum ether-ethyl acetate (7 : 3 ratio) gave CHM-09 (0.030 g, yield: 23.28%). The R f value of the compound CHM-09 was 0.402 (petroleum ether : ethyl acetate, 9 : 1). The purified compound was then characterised by physical and spectroscopic methods and was consistent with the desired structure.
Spectral data of chrysin analog (CHM-09) Cytotoxic effect on proliferation , 50 and 54°C) for 3 min, followed immediately by two cycles of freeze/thaw in liquid nitrogen at 25°C as described previously [19] . Cell lysates were centrifuged at 20 000 g for 20 min at 4°C and supernatant with the soluble protein fraction was subjected to SDS/PAGE and transferred onto a poly(vinylidene difluoride) membrane, and probed with antibodies EGFR and tubulin (loading control).
Effect on gene expression
Total RNA extracted from MCF-7 and MDA-MB-231 cells was used for cDNA synthesis (Thermo Scientific, Waltham, MA, USA). Human gene-specific forward and reverse primers of various growth factor receptors, as well as apoptotic and cell cycle genes, were utilized for semiquantitative RT-PCR and a quantitative real-time RT-PCR (Applied Biosystems, Foster City, CA, USA) analysis as described previously [46] . Amplification of eukaryotic 18S rRNA and b-actin was used as an internal control. All of the target gene expression was normalized to the internal control and is shown as the fold change.
Effect on protein expression
Cells treated with CHM-09 and EGFR inhibitors at different concentrations for 48 h were lysed and total protein isolated was subjected to SDS/PAGE, transferred to a poly(vinylidene difluoride) membrane and probed with various primary antibodies followed by incubation with horseradish peroxidase-conjugated secondary antibodies (Abcam, Cambridge, MA, USA) as described previously [47] .
Visualization was performed using G: Box (Syngene, Cambridge, UK).
BrdU cell cycle analysis
MDA-MB-231 cells treated with chrysin, CHM-09, AG1478 and PD153035 at 10 lM for 24 h followed by labelling with BrdU at a final concentration of 10 lM per 10 6 cells for 24 h. Cells were fixed with 5 mL of ice cold ethanol and incubated at 4°C overnight. Ethanol fixed cells were centrifuged and the cell pellet was re-dissolved in 2 N HCL/Triton X-100 and incubated for 30 min to denature the DNA. Next, cells were spin down and cell pellet was re-dissolved in 0.1 M sodium borate (Na 2 B 4 O 7 , pH 8.5) to neutralize the sample followed by re-suspension in 50 lL of 0.5% Tween 20/1% BSA/PBS. Cells were incubated with BrdU antibody (1 lg per 10 6 cells) for 1 h and then with secondary anti-mouse Alexa Flour 488 for 30 min at room temperature. Cells were resuspended in 0.2 mL of PBS containing propidium iodide (20 lgÁmL À1 ) and samples were then incubated in dark for 30 min followed by analysis using a flow cytometer (FlowSight; Amnis Corp., Seattle, WA, USA) as described previously [48] .
Effect on cellular apoptosis
The apoptosis assay was performed using an annexin-fluorescein isothiocyanate (FITC) staining kit (BioLegend, San Diego, CA, USA) and MDA-MB-231 cells treated with chrysin, CHM-09, AG1478 and PD153035 at 10 lM for 48 h as described previously [46] .
Isolation of breast CSCs by magnetic activated cell sorting
Breast CSCs were isolated from MDA-MB-231, MDA-MB-453, BT-549 and MDA-MB-468 using magnetic activated cell sorting (Miltenyi Biotec, Singapore, Singapore) as described previously [49] based on the absence and presence of CD24 and CD44 cell surface markers, respectively. Cells were subjected to immunodepletion by CD24 microbeads in accordance with the manufacturer's instructions. The CD24 À population was further subjected to CD44 selection to isolate CD24 À /CD44 + (breast CSCs). The sorted CD24 + and CD24 À /CD44 + cell populations were plated for subsequent experiments in the presence and absence of CHM-09 and PD153035 for cell viability assays and gene and protein expression analysis as described above.
Immunofluoroscence analysis
The sorted CD24 + and CD24 À /CD44 + cell populations were plated on the glass coverslips in a six-well plate for 24 h at 37°C. Cells were then fixed with methanol for 20 min and stained with CD24 and CD44 antibodies for 2 h at room temperature. Post incubation, cells were stained with fluorochrome-conjugated secondary antibodies and images were procured using a confocal microscope (Fluoview FV10i; Olympus, Macquarie Park, NSW, Australia).
Purity check of sorted populations
Expression of CD24 and CD44 in the sorted cell populations was evaluated using immunofluoroscence analysis under confocal microscopy as described previously [49] . Effect on mammosphere forming capacity of breast CSCs CD24 À /CD44 + cells were plated at a density of 1 9 10 4 cells/ well in 1 mL of mammosphere specific medium in poly hydroxyl ethyl methacrylate (Sigma-Aldrich) coated plates as described previously [51] . Cells were treated with PD153035 (5 lM) or CHM-09 at 0.1, 1 or 10 lM in the presence/absence of EGF (10 ngÁmL
À1
). After 7 days, the images of mammospheres were taken at 910 magnification using a microscope (IX71; Olympus, Tokyo, Japan). The size of spheres was measured using IMAGEJ (NIH, Bethesda, MD, USA).
Effect on breast CSC differentiation
The CD24
À /CD44 + sorted population was seeded in a 24-well plate at a density of 500 cells/well and treated with PD153035 (5 lM) or CHM-09 at 0.1 and 1 lM in the presence/absence of EGF (10 ngÁmL
À1
). The cells were maintained in adipocyte differentiation medium (dexamethasone, 1 lM; IBMX, 0.5 lM; insulin, 1000 ngÁmL À1 ) for 14 days.
For chondrocyte and osteoblast differentiation, cells were maintained in chondrocyte differentiation medium (dexamethasone, 0.1 lM; ascorbate-2-phosphate, 50 lM; ITS, 500 lL; sodium pyruvate, 1 mM; TGF-b-3, 1 lL; proline, 0.25 mgÁmL
) and osteoblast differentiation medium (dexamethasone, 0.1 lM; ascorbate-2-phosphate, 50 lM; b-glycerophosphate, 10 mM) for 21 and 28 days, respectively. Post differentiation, media were removed and stained with 300 lL of Oil red 'O' stain for adipocyte differentiation, toludine blue for chondrocyte differentiation and Von Kossa staining for osteoblast differentiation as described preivosuly [49] . Images were taken at 910 magnification.
Statistical analysis
The results are reported as the mean AE SEM of three or more independent experiments, which were performed in triplicate. Photomicrographs represent typical experiments reproduced at least three times with similar results being obtained. The quantitative analysis was performed using IM-AGEJ. Statistical analyses were performed to determine the difference between the treatment group and the respective controls using one-way ANOVA in PRISM, version 6.05 A Student's paired t-test. P < 0.05 was considered statistically significant.
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Supporting information
Additional Supporting Information may be found online in the supporting information tab for this article: Fig. S1 . Representative western blot analysis of EGFR expression in CD24 + and CD24 À /CD44 + cells depicting the relatively high expression of EGFR in CD24 À / CD44 + cells. Table S1 . Primer sequence of cell cycle, apoptosis and EMT specific markers.
